FI905941A - Förfarande för framställning av terapeutiskt användbara heterocykliska 2-acylaminotiazolderivat - Google Patents

Förfarande för framställning av terapeutiskt användbara heterocykliska 2-acylaminotiazolderivat Download PDF

Info

Publication number
FI905941A
FI905941A FI905941A FI905941A FI905941A FI 905941 A FI905941 A FI 905941A FI 905941 A FI905941 A FI 905941A FI 905941 A FI905941 A FI 905941A FI 905941 A FI905941 A FI 905941A
Authority
FI
Finland
Prior art keywords
preparation
therapeutically useful
useful heterocyclic
acylaminothiazole derivatives
acylaminothiazole
Prior art date
Application number
FI905941A
Other languages
English (en)
Finnish (fi)
Other versions
FI905941A0 (sv
FI94249B (sv
FI94249C (sv
Inventor
Jean-Pierre Bras
Daniel Frehel
Danielle Gully
Gerard Valette
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26227714&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI905941(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from FR8916122A external-priority patent/FR2655344B1/fr
Priority claimed from FR9005669A external-priority patent/FR2661677B1/fr
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of FI905941A0 publication Critical patent/FI905941A0/sv
Publication of FI905941A publication Critical patent/FI905941A/sv
Publication of FI94249B publication Critical patent/FI94249B/sv
Application granted granted Critical
Publication of FI94249C publication Critical patent/FI94249C/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Indole Compounds (AREA)
FI905941A 1989-12-06 1990-12-03 Förfarande för framställning av terapeutiskt användbara heterocykliska 2-acylaminotiazolderivat FI94249C (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR8916122A FR2655344B1 (fr) 1989-12-06 1989-12-06 Derives heterocycliques d'acylaminothiazoles, leur preparation et compositions pharmaceutiques en contenant.
FR8916122 1989-12-06
FR9005669 1990-05-04
FR9005669A FR2661677B1 (fr) 1990-05-04 1990-05-04 Derives heterocycliques d'acylaminothiazoles, leur preparation et compositions pharmaceutiques en contenant.

Publications (4)

Publication Number Publication Date
FI905941A0 FI905941A0 (sv) 1990-12-03
FI905941A true FI905941A (sv) 1991-06-07
FI94249B FI94249B (sv) 1995-04-28
FI94249C FI94249C (sv) 1995-08-10

Family

ID=26227714

Family Applications (1)

Application Number Title Priority Date Filing Date
FI905941A FI94249C (sv) 1989-12-06 1990-12-03 Förfarande för framställning av terapeutiskt användbara heterocykliska 2-acylaminotiazolderivat

Country Status (20)

Country Link
US (2) US5189049A (sv)
EP (1) EP0432040B2 (sv)
JP (2) JP2760903B2 (sv)
KR (1) KR0147281B1 (sv)
AR (1) AR248138A1 (sv)
AT (1) ATE109145T1 (sv)
AU (1) AU628696B2 (sv)
CA (1) CA2031463C (sv)
DE (1) DE69011059T3 (sv)
DK (1) DK0432040T3 (sv)
ES (1) ES2057490T5 (sv)
FI (1) FI94249C (sv)
GR (1) GR3025940T3 (sv)
HK (1) HK1002030A1 (sv)
HU (2) HU218276B (sv)
IE (1) IE68593B1 (sv)
IL (1) IL96577A (sv)
LV (1) LV5802B4 (sv)
MX (1) MX9203027A (sv)
NO (1) NO179584C (sv)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2677356B1 (fr) * 1991-06-05 1995-03-17 Sanofi Sa Derives heterocycliques d'acylamino-2 thiazoles-5 substitues, leur preparation et compositions pharmaceutiques en contenant.
US6558952B1 (en) * 1992-12-14 2003-05-06 Waratah Pharmaceuticals, Inc. Treatment for diabetes
FR2701708B1 (fr) * 1993-02-19 1995-05-19 Sanofi Elf Dérivés de 2-amido-4-phénylthiazoles polysubstitués, procédé de préparation, composition pharmaceutique et utilisation de ces dérivés pour la préparation d'un médicament.
FR2703995B1 (fr) * 1993-04-16 1995-07-21 Sanofi Elf 5-acylamino 1,2,4-thiadiazoles, leur preparation et compositions pharmaceutiques en contenant.
FR2754258B1 (fr) 1996-10-08 1998-12-31 Sanofi Sa Derives d'aminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
FR2768737B1 (fr) * 1997-09-19 2000-05-19 Sanofi Sa Derives de carboxamidothiazoles, leur preparation, les compositions pharmaceutiques en contenant
CO4970713A1 (es) * 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
CN1158269C (zh) 1997-10-27 2004-07-21 阿古龙制药公司 作为cdk抑制剂的取代的4-氨基-噻唑-2-基化合物
FR2781227B1 (fr) 1998-07-20 2002-02-22 Sanofi Sa Procede pour la preparation du sel potassique du lintitript
US20040037818A1 (en) * 1998-07-30 2004-02-26 Brand Stephen J. Treatment for diabetes
DE19908538A1 (de) * 1999-02-26 2000-08-31 Aventis Pharma Gmbh Polycyclische 2-Amino-Thiazol Systeme, Verfahren zu ihrer Herstellung und Arzneimittel enthaltend diese Verbindungen
DE19908537A1 (de) 1999-02-26 2000-08-31 Aventis Pharma Gmbh Verwendung von polycyclischen 2-Amino-Thiazol Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas
US6218408B1 (en) 1999-06-30 2001-04-17 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (bicyclics)
US6340683B1 (en) 1999-04-22 2002-01-22 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (triazines)
DE60034783T2 (de) 1999-04-22 2008-01-31 H. Lundbeck A/S, Valby Selektive npy(y5)-antagonisten
US6989379B1 (en) 1999-04-22 2006-01-24 H. Lundbick A/S Selective NPY (Y5) antagonists
US6214853B1 (en) 1999-06-30 2001-04-10 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (bicyclics)
US7273880B2 (en) 1999-06-30 2007-09-25 H. Lunbeck A/S Selective NPY (Y5) antagonists
US6222040B1 (en) 1999-06-30 2001-04-24 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (tricyclics)
US6225330B1 (en) 1999-06-30 2001-05-01 Synaptic Pharmaceutical Corporation Selective NPY (Y5) antagonists (tricyclics)
CA2399791A1 (en) 2000-02-11 2001-08-16 Bristol-Myers Squibb Company Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators in treating respiratory and non-respiratory diseases
WO2002009701A1 (en) * 2000-08-01 2002-02-07 University Of Virginia Patent Foundation Use of selective adenosine a1 receptor agonists, antagonists and allosteric enhancers to manipulate angiogenesis
JP2004520345A (ja) * 2001-01-12 2004-07-08 ワラター・ファーマシューティカルズ・インク 糖尿病を有する被験者にガストリン／ｃｃｋ受容体リガンド及びｅｇｆ受容体リガンド組成物を用いた島細胞新生治療方法の効果持続
WO2002059099A1 (fr) * 2001-01-26 2002-08-01 Shionogi & Co., Ltd. Composes cycliques presentant un agonisme envers le recepteur de thrombopoietine
US20040077697A1 (en) * 2001-02-02 2004-04-22 Hiroyuki Koshio 2-Acylaminothiazole derivative or its salt
EP1314733A1 (en) * 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
WO2003061655A1 (en) * 2002-01-16 2003-07-31 University Of Virginia Patent Foundation 2-aminothiazole allosteric enhancers of a1 adenosine receptors
US20050261298A1 (en) * 2002-01-18 2005-11-24 David Solow-Cordero Methods of treating conditions associated with an Edg-7 receptor
CN1319967C (zh) 2002-01-18 2007-06-06 安斯泰来制药有限公司 2－酰基氨基噻唑衍生物或其盐
CA2477604A1 (en) 2002-03-13 2003-09-25 Signum Biosciences, Inc. Modulation of protein methylation and phosphoprotein phosphate
US20060234373A1 (en) * 2002-05-24 2006-10-19 Alex Rabinovitch Treatment for diabetes
EP1837031B1 (en) * 2002-06-07 2009-10-14 Waratah Pharmaceuticals, Inc. Compositions and methods for treating diabetes
CA2744893A1 (en) 2002-06-27 2004-01-08 Novo Nordisk A/S Aryl carbonyl derivatives as glucokinase activators
US20040229810A1 (en) * 2002-10-22 2004-11-18 Antonio Cruz Gastrin compositions and formulations, and methods of use and preparation
US20080039379A1 (en) * 2003-05-27 2008-02-14 Waratah Pharmaceuticals, Inc. Compositions Comprising Gastrin Compounds and Their Use in Diabetes
US7737133B2 (en) * 2003-09-03 2010-06-15 Agi Therapeutics Ltd. Formulations and methods of treating inflammatory bowel disease
EP1532980A1 (en) * 2003-11-24 2005-05-25 Novo Nordisk A/S N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes
HUE025659T2 (en) * 2003-12-26 2016-04-28 Kyowa Hakko Kirin Co Ltd Thiazole derivatives
BRPI0506662B8 (pt) 2004-01-06 2021-05-25 Novo Nordisk As compostos ativadores de glucoquinase
EP1791822A1 (en) * 2004-08-05 2007-06-06 F.Hoffmann-La Roche Ag Substituted n-acyl-2-aminothiazoles
CA2575466A1 (en) * 2004-08-13 2006-02-23 Genentech, Inc. Thiazole based inhibitors of atp-utilizing enzymes
WO2006080406A1 (ja) * 2005-01-28 2006-08-03 Taisho Pharmaceutical Co., Ltd. 三環性化合物
WO2006084033A1 (en) * 2005-02-03 2006-08-10 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
US7923041B2 (en) 2005-02-03 2011-04-12 Signum Biosciences, Inc. Compositions and methods for enhancing cognitive function
JPWO2006137527A1 (ja) * 2005-06-23 2009-01-22 協和発酵キリン株式会社 チアゾール誘導体
ES2382815T3 (es) 2005-07-08 2012-06-13 Novo Nordisk A/S Dicicloalquilcarbamoil ureas como activadores de glucoquinasa
MX2008000255A (es) 2005-07-14 2008-04-02 Novo Nordisk As Activadores de urea glucocinasa.
JP2009514941A (ja) * 2005-11-08 2009-04-09 アステラス製薬株式会社 血小板減少症を治療する化合物および方法
CA2633569A1 (en) * 2005-12-12 2007-06-21 Genelabs Technologies, Inc. N-(5-membered heteroaromatic ring)-amido anti-viral compounds
CN101096363B (zh) * 2006-06-27 2011-05-11 中国人民解放军军事医学科学院毒物药物研究所 2,4,5-三取代噻唑类化合物、其制备方法、药物组合物及其制药用途
ES2470333T3 (es) * 2006-08-08 2014-06-23 Akarx, Inc. Composiciones y métodos para aumentar los niveles de plaquetas de la sangre en humanos
JP2010515701A (ja) 2007-01-09 2010-05-13 ノボ・ノルデイスク・エー／エス ウレアグルコキナーゼアクチベーター
US8318778B2 (en) 2007-01-11 2012-11-27 Novo Nordisk A/S Urea glucokinase activators
CA2758424C (en) 2008-04-21 2018-03-06 Signum Biosciences, Inc. Tryptamine derivatives as pp2a methylation modulators
EP2464352A1 (en) * 2009-08-14 2012-06-20 Eisai Inc. Use of e5501 for stimulating platelet production
DE102011083271A1 (de) * 2011-09-23 2013-03-28 Beiersdorf Ag Aromatische Amidothiazole, deren kosmetische oder dermatologische Verwendung sowie kosmetische oder dermatologische Zubereitungen mit einem Gehalt an solchen Aromatischen Amidothiazolen
EP3004057B1 (en) * 2013-06-05 2018-07-25 C&C Research Laboratories Heterocyclic derivatives and their use as stat 3 inhibitors
JP6434968B2 (ja) 2013-07-02 2018-12-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｒｏｃｋ阻害剤としての三環式ピリド−カルボキサミド誘導体
US9663529B2 (en) 2013-07-02 2017-05-30 Bristol-Myers Squibb Company Tricyclic pyrido-carboxamide derivatives as rock inhibitors
CN113321640B (zh) * 2017-06-22 2023-06-09 中国科学院广州生物医药与健康研究院 一种吲哚类化合物及其应用
KR20210020866A (ko) 2018-06-12 2021-02-24 브이티브이 테라퓨틱스 엘엘씨 인슐린 또는 인슐린 유사체와 조합된 글루코키나제 활성제의 치료적 용도

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2340092A2 (fr) * 1976-02-09 1977-09-02 Roussel Uclaf Nouveaux derives de l'acide 3-quinoleine carboxylique, leur procede de preparation et leur application comme medicament
AT367871B (de) * 1980-05-16 1982-08-10 Hoerbiger Ventilwerke Ag Anordnung zur selbsttaetigen druckentlastung von verdichtern
FR2482596A1 (fr) * 1980-05-19 1981-11-20 Roussel Uclaf Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2, leur procede de preparation et leur application comme medicament
JPS5978171A (ja) * 1982-10-26 1984-05-04 Ikeda Mohandou:Kk 複素環式化合物
FR2566405B1 (fr) * 1984-06-25 1986-09-26 Roussel Uclaf Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2 par une fonction aminee, leur preparation, leur application comme medicaments, les compositions les renfermant et les intermediaires nouveaux obtenus
EP0208510B1 (en) * 1985-07-09 1991-09-11 Pfizer Inc. 1-substituted oxindole-3-carboxamines as antiinflammatory and analgesic agents
DE3705934A1 (de) * 1987-02-25 1988-09-08 Nattermann A & Cie Indolyl-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US4971978A (en) * 1987-09-21 1990-11-20 Nadzan Alex M Derivatives of D-glutamic acid and D-aspartic acid
US4992437A (en) * 1987-12-22 1991-02-12 Yoshitomi Pharmaceutical Industries, Ltd. Thienodiazepine compounds and their pharmaceutical use
GB8804448D0 (en) * 1988-02-25 1988-03-23 Smithkline Beckman Intercredit Compounds
GB8820231D0 (en) * 1988-08-25 1988-09-28 Fujisawa Pharmaceutical Co New benzazole compounds processes for preparation thereof & pharmaceutical composition comprising same
FR2701708B1 (fr) * 1993-02-19 1995-05-19 Sanofi Elf Dérivés de 2-amido-4-phénylthiazoles polysubstitués, procédé de préparation, composition pharmaceutique et utilisation de ces dérivés pour la préparation d'un médicament.
FR2703995B1 (fr) * 1993-04-16 1995-07-21 Sanofi Elf 5-acylamino 1,2,4-thiadiazoles, leur preparation et compositions pharmaceutiques en contenant.

Also Published As

Publication number Publication date
HU218276B (en) 2000-07-28
MX9203027A (es) 1992-07-01
NO179584C (no) 1996-11-06
AU628696B2 (en) 1992-09-17
DE69011059T2 (de) 1995-03-02
JP3035253B2 (ja) 2000-04-24
NO905255L (no) 1991-06-07
HUT59400A (en) 1992-05-28
IL96577A0 (en) 1991-09-16
GR3025940T3 (en) 1998-04-30
IE68593B1 (en) 1996-06-26
FI905941A0 (sv) 1990-12-03
EP0432040A1 (fr) 1991-06-12
LV5802B4 (lv) 1997-08-20
KR910011814A (ko) 1991-08-07
IE904310A1 (en) 1991-06-19
NO179584B (no) 1996-07-29
DE69011059T3 (de) 1998-04-09
ATE109145T1 (de) 1994-08-15
NO905255D0 (no) 1990-12-05
ES2057490T3 (es) 1994-10-16
HU908075D0 (en) 1991-06-28
JPH10130147A (ja) 1998-05-19
JPH03279374A (ja) 1991-12-10
JP2760903B2 (ja) 1998-06-04
CA2031463C (en) 2000-07-25
DK0432040T3 (da) 1994-10-31
DE69011059D1 (de) 1994-09-01
EP0432040B1 (fr) 1994-07-27
HK1002030A1 (en) 1998-07-24
ES2057490T5 (es) 1998-03-16
CA2031463A1 (en) 1991-06-07
USRE37094E1 (en) 2001-03-13
LV5802A4 (lv) 1997-02-20
AU6777990A (en) 1991-06-20
FI94249B (sv) 1995-04-28
EP0432040B2 (fr) 1997-12-17
KR0147281B1 (ko) 1998-08-17
FI94249C (sv) 1995-08-10
US5189049A (en) 1993-02-23
HU211866A9 (en) 1995-12-28
AR248138A1 (es) 1995-06-30
IL96577A (en) 1994-06-24

Similar Documents

Publication Publication Date Title
FI905941A0 (sv) Förfarande för framställning av terapeutiskt användbara heterocykliska 2-acylaminotiazolderivat
FI96861C (sv) Förfarande för framställning av terapeutiskt aktiva substituerade indolylpyrrolderivat
FI890282A0 (sv) Förfarande för framställning av terapeutiskt användbara 23,24-didehydro-25-hydroxikalciferolderivat
FI104170B1 (sv) Förfarande för framställning av terapeutiskt användning 3-aminopyrazolderivat
FI880941A (sv) Förfarande för framställning av terapeutiskt användbara piperazinyl-heterocykliska föreningar
FI92934B (sv) Analogiförfarande för framställning av terapeutiskt användbara 1-deoxinojirimycinderivat
NO176759C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive 3-substituerte-2-oksindol-derivater
FI883064A (sv) Förfarande för framställning av terapeutiskt användbara heterocykliska föreningar
NO175978C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive bis-aza-bicykliske forbindelser
FI890072A0 (sv) Förfarande för framställning av farmaceutiskt användbara isokinolinderivat
FI930723A0 (sv) Förfarande för framställning av terapeutiskt aktiva tiazolidinderivat
FI896249A0 (sv) Förfarande för framställning av terapeutiskt användbara 7-oxabicykloheptylsubstituerade heterocykliska amidprostaglandinderivat
FI92696C (sv) Förfarande för framställning av terapeutiskt användbara tiazolidindionderivat
FI895393A0 (sv) Förfarande för framställning av terapeutiskt användbara alkylsubstituerade-2-alkylaminbensopyran-6-oler
FI883672A (sv) Förfarande för framställning av terapeutiskt användbara aminoalkoxifenylderivat
FI93444B (sv) Förfarande för framställning av terapeutiskt aktiva dihydropyridinföreningar
FI93106C (sv) Förfarande för framställning av som läkemedel användbara 2-iminobenzotiazolinderivat
FI893003A (sv) Förfarande för framställning av terapeutiskt användbara neplanocinderivat
FI895983A0 (sv) Förfarande för framställning av som läkemedel användbara 2-benzotiazolinderivat
FI903077A0 (sv) Förfarande för framställning av terapeutiskt aktiva R(-)-3-kinuklidinolderivat
FI911701A0 (sv) Förfarande för framställning av terapeutiskt användbara 2-substituerade-3-karboxikarbapenemer
EE03027B1 (et) Meetod 8-klorokinolooni derivaatide valmistamiseks
FI884473A (sv) Förfarande för framställning av terapeutiskt användbara fenoxialkylpyrokatekolderivat
PT87359A (pt) Process for the preparation of pyrrolidine derivatives
FI93216C (sv) Analogiförfarande för framställning av terapeutiskt användbara 1,3-dioxanalkensyraderivat

Legal Events

Date Code Title Description
BB Publication of examined application
MM Patent lapsed

Owner name: SANOFI-SYNTHELABO